Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Leukemia

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 39 articles: HTML format

Single Articles

June 2026
1. ANNAMALAY A, Radich J
   Chronic Myeloid Leukemia in Low- and Middle-Income Countries. Reply.
   N Engl J Med. 2026;394:2175-2176.
   PubMed    
   
   
   
2. MAHON FX, Rea D, Rousselot P
   Chronic Myeloid Leukemia in Low- and Middle-Income Countries.
   N Engl J Med. 2026;394:2175.
   PubMed    
   
   
   
3. ROBOZ GJ, Zeidan AM, Mannis GN, Montesinos P, et al
   All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia.
   N Engl J Med. 2026;394:2107-2116.
   PubMed     Abstract available
   
   
   March 2026
4. ANNAMALAY A, Garcia Gonzalez I, Forsyth C, Jenkins I, et al
   Treatment-free Remission in Chronic Myeloid Leukemia in Low- and Middle-Income Countries.
   N Engl J Med. 2026;394:1238-1240.
   PubMed    
   
   
   December 2025
5. CHIESA R, Georgiadis C, Rashed H, Preece R, et al
   Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia.
   N Engl J Med. 2025 Dec 8. doi: 10.1056/NEJMoa2505478.
   PubMed     Abstract available
   
   
   
6. AL-SAWAF O, Stumpf J, Zhang C, Simon F, et al
   Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.
   N Engl J Med. 2025 Dec 6. doi: 10.1056/NEJMoa2515458.
   PubMed     Abstract available
   
   
   
7. MUNIR T, Cairns DA, Hillmen P
   Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia. Reply.
   N Engl J Med. 2025;393:2280.
   PubMed    
   
   
   
8. WANG Y, Zhu Z, Liang Y
   Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.
   N Engl J Med. 2025;393:2279-2280.
   PubMed    
   
   
   
9. FLEISCHMAN RA
   Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.
   N Engl J Med. 2025;393:2279.
   PubMed    
   
   
   June 2025
10. MUNIR T, Girvan S, Cairns DA, Bloor A, et al
    Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.
    N Engl J Med. 2025 Jun 15. doi: 10.1056/NEJMoa2504341.
    PubMed     Abstract available
    
    
    
11. GUPTA S, Rau RE, Loh ML
    Blinatumomab in Childhood B-Cell Acute Lymphoblastic Leukemia. Reply.
    N Engl J Med. 2025;392:2286-2287.
    PubMed    
    
    
    
12. HODDER A, Vora A, Samarasinghe S
    Blinatumomab in Childhood B-Cell Acute Lymphoblastic Leukemia.
    N Engl J Med. 2025;392:2286.
    PubMed    
    
    
    
13. BROWN JR, Miller K, Munugalavadla V
    Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia. Reply.
    N Engl J Med. 2025;392:2181.
    PubMed    
    
    
    
14. MOHTY M, Kharfan-Dabaja MA
    Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.
    N Engl J Med. 2025;392:2180-2181.
    PubMed    
    
    
    May 2025
15. FOA R
    Ph-Positive Acute Lymphoblastic Leukemia - 25 Years of Progress.
    N Engl J Med. 2025;392:1941-1952.
    PubMed    
    
    
    April 2025
16. SANTI A, Venanzi A, Pucciarini A, Schiavoni G, et al
    Targetable Mutations in BRAF V600E-Negative Hairy-Cell Leukemia.
    N Engl J Med. 2025;392:1451-1452.
    PubMed    
    
    
    February 2025
17. BROWN JR, Seymour JF, Jurczak W, Aw A, et al
    Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.
    N Engl J Med. 2025;392:748-762.
    PubMed     Abstract available
    
    
    January 2025
18. BASHIR BA
    Chronic Myeloid Leukemia with Hyperleukocytosis.
    N Engl J Med. 2025;392:72.
    PubMed    
    
    
    December 2024
19. FALINI B, Tiacci E
    Hairy-Cell Leukemia. Reply.
    N Engl J Med. 2024;391:2388.
    PubMed    
    
    
    
20. HERMEL DJ, Saven A
    Hairy-Cell Leukemia.
    N Engl J Med. 2024;391:2387-2388.
    PubMed    
    
    
    
21. REINHOLD I, Cornely OA, Stemler J
    Hairy-Cell Leukemia.
    N Engl J Med. 2024;391:2386-2387.
    PubMed    
    
    
    
22. ABRUZZESE E
    Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. Reply.
    N Engl J Med. 2024;391:2276.
    PubMed    
    
    
    
23. HOCHHAUS A, Cortes JE, Hughes TP
    Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. Reply.
    N Engl J Med. 2024;391:2275-2276.
    PubMed    
    
    
    
24. PUNWANI N
    Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
    N Engl J Med. 2024;391:2275.
    PubMed    
    
    
    
25. GAMBACORTI-PASSERINI C, Piazza R
    Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
    N Engl J Med. 2024;391:2274-2275.
    PubMed    
    
    
    
26. GUPTA S, Rau RE, Kairalla JA, Rabin KR, et al
    Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.
    N Engl J Med. 2024 Dec 7. doi: 10.1056/NEJMoa2411680.
    PubMed     Abstract available
    
    
    November 2024
27. RODDIE C, Sandhu KS, Tholouli E, Logan AC, et al
    Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic Leukemia.
    N Engl J Med. 2024 Nov 27. doi: 10.1056/NEJMoa2406526.
    PubMed     Abstract available
    
    
    October 2024
28. FALINI B, Tiacci E
    Hairy-Cell Leukemia.
    N Engl J Med. 2024;391:1328-1341.
    PubMed    
    
    
    September 2024
29. ABRUZZESE E
    CML 25 Years Later - Poised for Another Breakthrough?
    N Engl J Med. 2024;391:955-957.
    PubMed    
    
    
    August 2024
30. HSU C, Konner JA, Gounder MM
    Epigenetic Therapy in a Rare Ovarian Cancer - A Double-Edged Sword.
    N Engl J Med. 2024;391:770-772.
    PubMed    
    
    
    July 2024
31. LITZOW MR, Sun Z, Mattison RJ, Paietta EM, et al
    Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.
    N Engl J Med. 2024;391:320-333.
    PubMed     Abstract available
    
    
    June 2024
32. TIONG IS, Ritchie DS, Blombery P
    Response and Resistance to Menin Inhibitor in UBTF-Tandem Duplication AML.
    N Engl J Med. 2024;390:2323-2325.
    PubMed    
    
    
    May 2024
33. HOCHHAUS A, Wang J, Kim DW, Kim DDH, et al
    Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
    N Engl J Med. 2024 May 31. doi: 10.1056/NEJMoa2400858.
    PubMed     Abstract available
    
    
    
34. MUNIR T, Hillmen P
    Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. Reply.
    N Engl J Med. 2024;390:1634-1635.
    PubMed    
    
    
    
35. WANG WD, Gale RP, Liang Y
    Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
    N Engl J Med. 2024;390:1633-1634.
    PubMed    
    
    
    
36. WINKLER C
    Acute Promyelocytic Leukemia.
    N Engl J Med. 2024;390:e42.
    PubMed    
    
    
    April 2024
37. BLAISE D
    CAR as Booster to Launch Allogeneic Transplantation in Refractory Leukemia.
    N Engl J Med. 2024;390:1526-1527.
    PubMed    
    
    
    
38. HU Y, Zhang M, Yang T, Mo Z, et al
    Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
    N Engl J Med. 2024;390:1467-1480.
    PubMed     Abstract available
    
    
    December 2023
39. MUNIR T, Cairns DA, Bloor A, Allsup D, et al
    Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
    N Engl J Med. 2023 Dec 10. doi: 10.1056/NEJMoa2310063.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum